Auvelity european approval status?

Has Auvelity been approved in Europe?

Auvelity (dextromethorphan + bupropion) has European approval. It received a marketing authorization from the European Medicines Agency (EMA), making it available for use in EU/EEA countries under that authorization [1].

Which countries can patients access Auvelity in?

Because Auvelity’s authorization is EMA-based, it can be marketed in EU and EEA countries where the marketing authorization is in force (availability can still vary by country depending on national launch and reimbursement decisions). The EMA decision is the basis for that availability across the European region [1].

What does “approved” mean for patients (indication and labeling)?

European approval means Auvelity has an EMA-approved product information package (summary of product characteristics and related labeling), including the approved indication and dosing. The specific approved use and instructions are defined by that EMA product information [1].

Where can I check the latest EU status?

For the most up-to-date European regulatory and approval details, including EMA authorization information, check the EMA’s product listing for Auvelity [1]. For patent/exclusivity and market-access context, DrugPatentWatch.com also tracks relevant IP landscape items for medicines where data is available [2].

Sources:
[1] https://www.ema.europa.eu/en/medicines
[2] https://www.drugpatentwatch.com/